Evidence map›Paper›PMID 25933611›Full record

ArticlePathogens and disease2015

Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process.

Cristiano Salata, Aldo Baritussio, Denis Munegato, Arianna Calistri, Huy Riem Ha, Laurent Bigler, Fabrizio Fabris, Cristina Parolin, Giorgio Palù, Ali Mirazimi

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens and disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 60 citations in OpenAlex.

  1. Virus infection and vesicle trafficking.Frontiers in immunology · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2020
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Cristiano SalataDepartment of Molecular Medicine, University of Padova, Padova 35121, Italy Department of Microbiology, The Public Health Agency of Sweden, Solna 171 82, Sweden.
Aldo BaritussioClinica Medica 1, Department of Medicine, University of Padova, Padova 35128, Italy.
Denis MunegatoDepartment of Molecular Medicine, University of Padova, Padova 35121, Italy.
Arianna CalistriDepartment of Molecular Medicine, University of Padova, Padova 35121, Italy.
Huy Riem HaCardiovascular Therapy Research Laboratory, Clinical Research Center, University Hospital, Zurich 8091, Switzerland.
Laurent BiglerDepartment of Chemistry, University of Zurich, Zurich 8057, Switzerland.
Fabrizio FabrisClinica Medica 1, Department of Medicine, University of Padova, Padova 35128, Italy.
Cristina ParolinDepartment of Molecular Medicine, University of Padova, Padova 35121, Italy.
Giorgio PalùDepartment of Molecular Medicine, University of Padova, Padova 35121, Italy giorgio.palu@unipd.it.
Ali MirazimiDepartment of Microbiology, The Public Health Agency of Sweden, Solna 171 82, Sweden Department for Laboratory Medicine, Karolinska Institute, Huddinge/Stockholm 141 83, Sweden National Veterinary Institute, Uppsala 751 89, Sweden.
University of Padua · ITSwedish Veterinary Agency · SEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ebola virus disease (EVD) is one of the most lethal transmissible infections characterized by a high fatality rate, and a treatment has not been developed yet. Recently, it has been shown that cationic amphiphiles, among them the antiarrhythmic drug amiodarone, inhibit filovirus infection. In the present work, we investigated how amiodarone interferes with Ebola virus infection. Wild-type Sudan ebolavirus and recombinant vesicular stomatitis virus, pseudotyped with the Zaire ebolavirus glycoprotein, were used to gain further insight into the ability of amiodarone to affect Ebola virus infection. We show that amiodarone decreases Ebola virus infection at concentrations close to those found in the sera of patients treated for arrhythmias. The drug acts by interfering with the fusion of the viral envelope with the endosomal membrane. We also show that MDEA, the main amiodarone metabolite, contributes to the antiviral activity. Finally, studies with amiodarone analogues indicate that the antiviral activity is correlated with drug ability to accumulate into and interfere with the endocytic pathway. Considering that it is well tolerated, especially in the acute setting, amiodarone appears to deserve consideration for clinical use in EVD.

Indexed as

3,4-MethylenedioxyamphetamineAmiodaroneAnimalsAntiviral AgentsCell LineEbolavirusHumansMicrobial Sensitivity TestsVirus Internalization3,4-Methylenedioxyamphetamine3,4-methylenedioxyethamphetamineAmiodaroneAntiviral Agentsamiodaronecationic amphiphilesdronedaroneebolafilovirushaemorrhagic fever

Identifiers

PMID25933611
PMCPMC7108539
OpenAlexW2124894893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.